Oxamniquine

Summary

Oxamniquine (CHEMBL847) is an approved small molecule (ATC P02BA02); indicated across 1 condition including helminthiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02BA02
• Indications: 1 condition
• Chemistry: 279.33 Da · C14H21N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL847
Name	Oxamniquine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4612
ChEBI	CHEBI:78416
ATC	P02BA02
Molecular formula	C14H21N3O3
Molecular weight	279.33
InChIKey	XCGYUJZMCCFSRP-UHFFFAOYSA-N

SMILES: CC(C)NCC1CCC2=CC(=C(C=C2N1)[N+](=O)[O-])CO

IUPAC name: [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol

ChEBI definition: A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.

Also known as: Mansil, NSC-352888, Oxamniquina, Oxamniquine, Oxamniquinum, UK-4261, UK-4271, Vansil, oxamniquine, SID26665195, OXAMNIQUINE, SID144204144

Patent coverage: 1,114 distinct patent families (4,186 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,931 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Beta-lactamase, Sodium-dependent serotonin transporter, D(3) dopamine receptor, Kappa-type opioid receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	5.13	AC50	7400	nM	CHEMBL_ACT_25193171

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
helminthiasis	4	MONDO:0004664	EFO:1001342

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).